{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:44:44Z","timestamp":1785026684909,"version":"3.55.0"},"reference-count":56,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Purpose: Glioblastoma often recurs after treatment. Bevacizumab increases progression-free survival in some patients with recurrent glioblastoma. Identifying pretreatment predictors of survival can help clinical decision making. Magnetic resonance texture analysis (MRTA) quantifies macroscopic tissue heterogeneity indirectly linked to microscopic tissue properties. We investigated the usefulness of MRTA in predicting survival in patients with recurrent glioblastoma treated with bevacizumab. Methods: We evaluated retrospective longitudinal data from 33 patients (20 men; mean age 56 \u00b1 13 years) who received bevacizumab on the first recurrence of glioblastoma. Volumes of contrast-enhancing lesions segmented on postcontrast T1-weighted sequences were co-registered on apparent diffusion coefficient maps to extract 107 radiomic features. To assess the performance of textural parameters in predicting progression-free survival and overall survival, we used receiver operating characteristic curves, univariate and multivariate regression analysis, and Kaplan\u2013Meier plots. Results: Longer progression-free survival (&gt;6 months) and overall survival (&gt;1 year) were associated with lower values of major axis length (MAL), a lower maximum 2D diameter row (m2Ddr), and higher skewness values. Longer progression-free survival was also associated with higher kurtosis, and longer overall survival with higher elongation values. The model combining MAL, m2Ddr, and skewness best predicted progression-free survival at 6 months (AUC 0.886, 100% sensitivity, 77.8% specificity, 50% PPV, 100% NPV), and the model combining m2Ddr, elongation, and skewness best predicted overall survival (AUC 0.895, 83.3% sensitivity, 85.2% specificity, 55.6% PPV, 95.8% NPV). Conclusions: Our preliminary analyses suggest that in patients with recurrent glioblastoma pretreatment, MRTA helps to predict survival after bevacizumab treatment.<\/jats:p>","DOI":"10.3390\/cancers15113026","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T01:33:54Z","timestamp":1685669634000},"page":"3026","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Texture Analysis of the Apparent Diffusion Coefficient Focused on Contrast-Enhancing Lesions in Predicting Survival for Bevacizumab-Treated Patients with Recurrent Glioblastoma"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7914-9948","authenticated-orcid":false,"given":"Antonio","family":"Lopez-Rueda","sequence":"first","affiliation":[{"name":"Department of Radiology (CDI), Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2791-6599","authenticated-orcid":false,"given":"Josep","family":"Puig","sequence":"additional","affiliation":[{"name":"Department of Radiology (IDI) and IDIBGI Hospital Universitari de Girona Doctor Josep Trueta, 17190 Girona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Thi\u00f3-Henestrosa","sequence":"additional","affiliation":[{"name":"Department of Computer Science Applied Mathmatics and Statistics, University of Girona, 17003 Girona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Luis","family":"Moreno-Negrete","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Iribas-IRM Asunci\u00f3n Paraguay, Asuncion 1430, Paraguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Zwanzger","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hospital Del Mar, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Pujol","sequence":"additional","affiliation":[{"name":"Department of Radiology (CDI), Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5774-7453","authenticated-orcid":false,"given":"Iban","family":"Aldecoa","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2128-747X","authenticated-orcid":false,"given":"Estela","family":"Pineda","sequence":"additional","affiliation":[{"name":"Translational Genomics and Targeted Therapeutics in Solid Tumors Group, Medical Oncology Department, Hospital Cl\u00ednic de Barcelona, IDIBAPS, University of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izaskun","family":"Valduvieco","sequence":"additional","affiliation":[{"name":"Radiotherapy Oncology Service, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Juan","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Laboratory of Experimental Oncological Neurosurgery, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9702-0451","authenticated-orcid":false,"given":"Laura","family":"Oleaga","sequence":"additional","affiliation":[{"name":"Department of Radiology (CDI), Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014\u20132018","volume":"23","author":"Ostrom","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Grochans, S., Cybulska, A.M., Simi\u0144ska, D., Korbecki, J., Kojder, K., Chlubek, D., and Baranowska-Bosiacka, I. (2022). Epidemiology of Glioblastoma Multiforme\u2013Literature Review. Cancers, 14.","DOI":"10.3390\/cancers14102412"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"574012","DOI":"10.3389\/fonc.2020.574012","article-title":"A Review of Newly Diagnosed Glioblastoma","volume":"10","author":"Oronsky","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fneur.2019.00286","article-title":"A Meta-Analysis of Survival Outcomes Following Reoperation in Recurrent Glioblastoma: Time to Consider the Timing of Reoperation","volume":"10","author":"Zhao","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/1078155216681191","article-title":"Clinical effectiveness of bevacizumab in patients with re-current brain tumours: A population-based evaluation","volume":"24","author":"Markarian","year":"2018","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/neuonc\/nov031","article-title":"Toward precision medicine in glioblastoma: The promise and the challenges","volume":"17","author":"Prados","year":"2015","journal-title":"Neuro-Oncology"},{"key":"ref_7","first-page":"471","article-title":"One size should not fit all: Advancing toward personalized glioblastoma therapy","volume":"19","author":"Reardon","year":"2015","journal-title":"Discov. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/PPO.0b013e3182431c6f","article-title":"Antiangiogenic Therapy for Glioblastoma","volume":"18","author":"Gerstner","year":"2012","journal-title":"Cancer J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s12032-019-1329-2","article-title":"The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: Perspectives for therapeutic implications","volume":"37","author":"Tamura","year":"2019","journal-title":"Med. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1212\/01.wnl.0000345668.03039.90","article-title":"Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience","volume":"72","author":"Nghiemphu","year":"2009","journal-title":"Neurology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.2010.30.2729","article-title":"Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multi-forme","volume":"29","author":"Lai","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/neuonc\/nou029","article-title":"A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma","volume":"16","author":"Clarke","year":"2014","journal-title":"Neuro-Oncology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus Radiotherapy\u2013Temozolomide for Newly Diagnosed Glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1053\/j.sult.2021.07.006","article-title":"Diffusion-Weighted Imaging: Recent Advances and Applica-tions","volume":"42","author":"Grussu","year":"2021","journal-title":"Semin. Ultrasound CT MR"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/ncponc1073","article-title":"Technology Insight: Water diffusion MRI\u2014A potential new biomarker of response to cancer therapy","volume":"5","author":"Patterson","year":"2008","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1200\/JCO.2007.11.9610","article-title":"Diffusion Magnetic Resonance Imaging: A Biomarker for Treatment Response in Oncology","volume":"25","author":"Hamstra","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1148\/radiol.2521081534","article-title":"Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment","volume":"252","author":"Pope","year":"2009","journal-title":"Radiology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11060-009-9981-6","article-title":"Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker","volume":"96","author":"Jain","year":"2009","journal-title":"J. Neuro-Oncology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/197140090601900308","article-title":"Is there a role for apparent diffusion coefficients in the differential diagnosis of brain tumors?","volume":"19","author":"Tokgoz","year":"2006","journal-title":"Neuroradiol. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3174\/ajnr.A2385","article-title":"Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma","volume":"32","author":"Pope","year":"2011","journal-title":"Am. J. Neuroradiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11060-012-0847-y","article-title":"Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: A multi-center study","volume":"108","author":"Pope","year":"2012","journal-title":"J. Neuro-Oncology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11060-010-0293-7","article-title":"Volumetric analysis of func-tional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas","volume":"102","author":"Ellingson","year":"2011","journal-title":"J. Neuro-Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/neuonc\/nor079","article-title":"Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab","volume":"13","author":"Ellingson","year":"2011","journal-title":"Neuro-Oncology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/jmri.21732","article-title":"Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme","volume":"29","author":"Paldino","year":"2009","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3174\/ajnr.A6075","article-title":"Texture Analysis in Cerebral Gliomas: A Review of the Literature","volume":"40","author":"Soni","year":"2019","journal-title":"Am. J. Neuroradiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3389\/fonc.2019.00374","article-title":"Radiomics in Glioblastoma: Current Status and Challenges Facing Clinical Implementation","volume":"9","author":"Chaddad","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.1118\/1.4934373","article-title":"Evaluation of tumor-derived MRI-texture features for discrimination of molecular subtypes and prediction of 12-month survival status in glioblastoma","volume":"42","author":"Yang","year":"2015","journal-title":"Med. Phys."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"14435","DOI":"10.1038\/s41598-019-50849-y","article-title":"Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma","volume":"9","author":"Sasaki","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_32","first-page":"859","article-title":"Relative cerebral blood volume maps corrected for contrast agent extrav-asation significantly correlate with glioma tumor grade, whereas uncorrected maps do not","volume":"27","author":"Boxerman","year":"2006","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","article-title":"3D Slicer as an image computing platform for the Quantitative Imaging Network","volume":"30","author":"Fedorov","year":"2012","journal-title":"Magn. Reson. Imaging"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1158\/0008-5472.CAN-17-0339","article-title":"Computational radiomics system to decode the radiographic phenotype","volume":"77","author":"Fedorov","year":"2017","journal-title":"Can. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.1002\/mp.13844","article-title":"Technical Note: Ontology-guided radiomics analysis workflow (O-RAW)","volume":"46","author":"Shi","year":"2019","journal-title":"Med. Phys."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Pasqualetti, F., Giampietro, C., Montemurro, N., Giannini, N., Gadducci, G., Orlandi, P., Natali, E., Chiarugi, P., Gonnelli, A., and Cantarella, M. (2022). Old and New Systemic Immune-Inflammation Indexes Are Associated with Overall Survival of Glioblastoma Patients Treated with Radio-Chemotherapy. Genes, 13.","DOI":"10.3390\/genes13061054"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s11547-022-01502-8","article-title":"Role of magnetic resonance imaging following postoperative radiotherapy in clinical decision-making of patients with high-grade glioma","volume":"127","author":"Pasqualetti","year":"2022","journal-title":"La Radiol. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/bs.irn.2020.03.009","article-title":"Advanced multimodal imaging in dif-ferentiating glioma recurrence from post-radiotherapy changes","volume":"151","author":"Li","year":"2020","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-009-9897-1","article-title":"Glioma recurrence versus radia-tion necrosis: Accuracy of current imaging modalities","volume":"95","author":"Alexiou","year":"2009","journal-title":"J. Neuro-Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/1971400921990766","article-title":"Survival prediction in glioblastoma on post-contrast magnetic resonance imaging using filtration based first-order texture analysis: Comparison of multiple machine learning models","volume":"34","author":"Priya","year":"2021","journal-title":"Neuroradiol. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"108642","DOI":"10.1016\/j.ejrad.2019.108642","article-title":"Analysis of heterogeneity of peritumoral T2 hyperintensity in patients with pre-treatment glioblastoma: Prognostic value of MRI-based radiomics","volume":"120","author":"Choi","year":"2019","journal-title":"Eur. J. Radiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/RLI.0000000000000349","article-title":"Radiomic Analysis Reveals Prognostic Information in T1-Weighted Baseline Magnetic Resonance Imaging in Patients With Glioblastoma","volume":"52","author":"Ingrisch","year":"2017","journal-title":"Investig. Radiol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Upadhaya, T., Morvan, Y., Stindel, E., Le Reste, P.J., and Hatt, M. (2015, January 16\u201319). Prognostic value of multimodal MRI tumor features in Glio-blastoma multiforme using textural features analysis. Proceedings of the 2015 IEEE 12th International Symposium on Bio-medical Imaging (ISBI), Brooklyn, NY, USA.","DOI":"10.1109\/ISBI.2015.7163814"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/neuonc\/nox092","article-title":"Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab","volume":"19","author":"Grossmann","year":"2017","journal-title":"Neuro-Oncology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"636672","DOI":"10.3389\/fonc.2021.636672","article-title":"Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial","volume":"11","author":"Vils","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7632","DOI":"10.1038\/s41598-021-84331-5","article-title":"Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET","volume":"11","author":"Huang","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3174\/ajnr.A3748","article-title":"Pretreatment ADC Histogram Analysis Is a Predictive Imaging Biomarker for Bevacizumab Treatment but Not Chemotherapy in Recurrent Glioblastoma","volume":"35","author":"Ellingson","year":"2013","journal-title":"Am. J. Neuroradiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"vdab082","DOI":"10.1093\/noajnl\/vdab082","article-title":"Val-idation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma","volume":"3","author":"Ellingson","year":"2021","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/neuros\/nyaa135","article-title":"Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden","volume":"87","author":"Patel","year":"2020","journal-title":"Neurosurgery"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3174\/ajnr.A7406","article-title":"Pretreatment ADC Histogram Analysis as a Prognostic Imaging Biomarker for Patients with Recurrent Glioblastoma Treated with Bevaci-zumab: A Systematic Review and Meta-analysis","volume":"43","author":"Kurokawa","year":"2022","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1148\/radiol.2016150702","article-title":"Intravoxel Incoherent Motion\u2013derived Histogram Metrics for Assessment of Response after Combined Chemotherapy and Radiation Therapy in Rectal Cancer: Initial Experience and Comparison between Single-Section and Volumetric Analyses","volume":"280","author":"Nougaret","year":"2016","journal-title":"Radiology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1148\/radiol.12112120","article-title":"Percent Change of Perfusion Skewness and Kurtosis: A Potential Imaging Biomarker for Early Treatment Response in Patients with Newly Diagnosed Glioblastomas","volume":"264","author":"Baek","year":"2012","journal-title":"Radiology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1200\/JCO.19.00367","article-title":"Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study","volume":"38","author":"Draaisma","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/neuonc\/nox188","article-title":"Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma","volume":"20","author":"Kickingereder","year":"2017","journal-title":"Neuro-Oncology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1158\/1078-0432.CCR-16-0702","article-title":"Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response","volume":"22","author":"Kickingereder","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/cncr.32790","article-title":"Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma","volume":"126","author":"Akbari","year":"2020","journal-title":"Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/11\/3026\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:47:23Z","timestamp":1760125643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/11\/3026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":56,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["cancers15113026"],"URL":"https:\/\/doi.org\/10.3390\/cancers15113026","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]}}}